Literature DB >> 9731577

Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.

R Burioni1, P Plaisant, A Manzin, D Rosa, V Delli Carri, F Bugli, L Solforosi, S Abrignani, P E Varaldo, G Fadda, M Clementi.   

Abstract

Demonstration of antibodies inhibiting key viral functions is the basis for the design of an effective vaccine. Dissection of the human antibody response by repertoire cloning may be a powerful means to address this issue. In this study, a panel of human monoclonal recombinant Fab fragments specific for hepatitis C virus (HCV) E2 envelope protein was generated. The selection procedure was designed to select for cross-genotype reactive antibodies. Sequences coding five different human recombinant Fabs specific for the HCV/E2 protein were cloned and characterized. The ability of the cloned antibody fragments to inhibit adhesion of recombinant envelope E2 protein to target cells was assayed. While affinity of the different antibody fragments appeared similar, activity in inhibiting E2 binding to target cells varied considerably from one Fab fragment to another. Two Fabs were not able to inhibit E2 binding at high concentration (40 microg/mL), while three other Fab clones were active in neutralizing 50% of the E2 binding at concentrations ranging from 3 to 0.35 microg/mL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731577     DOI: 10.1002/hep.510280331

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

3.  Evidence for prostaglandin-producing supressor cells in HCV patients with normal ALT.

Authors:  Rui Marinho; Ruth Pinto; Maria Livia Santos; MouraMiguelCarneiro de
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

4.  Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries.

Authors:  F Bugli; N Mancini; C Y Kang; C Di Campli; A Grieco; A Manzin; A Gabrielli; A Gasbarrini; G Fadda; P E Varaldo; M Clementi; R Burioni
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype.

Authors:  Roberto Burioni; Yoshiharu Matsuura; Nicasio Mancini; Hideki Tani; Tatsuo Miyamura; Pietro E Varaldo; Massimo Clementi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

8.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

9.  Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses.

Authors:  Alessandra Desogus; Roberto Burioni; Angela Ingianni; Francesca Bugli; Raffaello Pompei; Giovanni Fadda
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

10.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.